ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
SO WHAT: If you purchased ESSA Pharma Inc. securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the ESSA Pharma Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=34133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants, throughout the Class Period, failed to disclose to investors that: (1) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (2) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (3) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint; (4) accordingly, defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the ESSA Pharma Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=34133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
4 minutes ago
- Chicago Tribune
President Donald Trump thinks owning a piece of Intel would be a good deal for the US. Here's what to know
SAN FRANCISCO — President Donald Trump wants the U.S. government to own a piece of Intel, less than two weeks after demanding the Silicon Valley pioneer dump the CEO that was hired to turn around the slumping chipmaker. If the goal is realized, the investment would deepen the Trump administration's involvement in the computer industry as the president ramps up the pressure for more U.S. companies to manufacture products domestically instead of relying on overseas suppliers. The Trump administration is in talks to secure a 10% stake in Intel in exchange for converting government grants that were pledged to Intel under President Joe Biden. If the deal is completed, the U.S. government would become one of Intel's largest shareholders and blur the traditional lines separating the public sector and private sector in a country that remains the world's largest economy. In his second term, Trump has been leveraging his power to reprogram the operations of major computer chip companies. The administration is requiring Nvidia and Advanced Micro Devices, two companies whose chips are helping to power the craze around artificial intelligence, to pay a 15% commission on their sales of chips in China in exchange for export licenses. Trump's interest in Intel is also being driven by his desire to boost chip production in the U.S., which has been a focal point of the trade war that he has been waging throughout the world. By lessening the country's dependence on chips manufactured overseas, the president believes the U.S. will be better positioned to maintain its technological lead on China in the race to create artificial intelligence. That's what the president said August 7 in an unequivocal post calling for Intel CEO Lip-Bu Tan to resign less than five months after the Santa Clara, California, company hired him. The demand was triggered by reports raising national security concerns about Tan's past investments in Chinese tech companies while he was a venture capitalist. But Trump backed off after Tan professed his allegiance to the U.S. in a public letter to Intel employees and went to the White House to meet with the president, who applauded the Intel CEO for having an 'amazing story.' The company isn't commenting about the possibility of the U.S. government becoming a major shareholder, but Intel may have little choice because it is currently dealing from a position of weakness. After enjoying decades of growth while its processors powered the personal computer boom, the company fell into a slump after missing the shift to the mobile computing era unleashed by the iPhone's 2007 debut. Intel has fallen even farther behind in recent years during an artificial intelligence craze that has been a boon for Nvidia and AMD. The company lost nearly $19 billion last year and another $3.7 billion in the first six months of this year, prompting Tan to undertake a cost-cutting spree. By the end of this year, Tan expects Intel to have about 75,000 workers, a 25% reduction from the end of last year. Although rare, it's not unprecedented for the U.S. government to become a significant shareholder in a prominent company. One of the most notable instances occurred during the Great Recession in 2008 when the government injected nearly $50 billion into General Motors in return for a roughly 60% stake in the automaker at a time it was on the verge of bankruptcy. The government ended up with a roughly $10 billion loss after it sold its stock in GM. U.S. Commerce Secretary Howard Lutnick told CNBC during a Tuesday interview that the government has no intention of meddling in Intel's business, and will have its hands tied by holding non-voting shares in the company. But some analysts wonder if the Trump administration's financial ties to Intel might prod more companies looking to curry favor with the president to increase their orders for the company's chips. Intel was among the biggest beneficiaries of the Biden administration's CHIPS and Science Act, but it hasn't been able to revive its fortunes while falling behind on construction projects spawned by the program. The company has received about $2.2 billion of the $7.8 billion pledged under the incentives program — money that Lutnick derided as a 'giveaway' that would better serve U.S. taxpayers if it's turned into Intel stock. 'We think America should get the benefit of the bargain,' Lutnick told CNBC. 'It's obvious that it's the right move to make.'
Chicago Tribune
4 minutes ago
- Chicago Tribune
Wall Street drifts in premarket trading while Target tumbles on sluggish sales and a CEO change
Wall Street continues to drift Wednesday while news of a leadership change at Target took some of the spotlight away from the latest batch of corporate earnings reports. Futures for the S&P 500 were 0.2% lower before the bell, while the Dow Jones Industrial Average inched back just 0.1%. Nasdaq futures fell 0.3%. Target tumbled 9% after the struggling Minneapolis retailer said that CEO Brian Cornell plans to step down Feb. 1. Chief Operating Officer Michael Fiddelke, a 20-year company veteran, will succeed Cornell, who helped reenergize the company but has struggled to turn around weak sales in a more competitive post-COVID retail landscape. Target also reported Wednesday that comparable store sales fell 1.9% in the period, a measure that has been flat or declined in eight out of the past 10 quarters. On the winning side was home improvement retailer Lowe's, which jumped 3.4% after it beat Wall Street's sales and profit expectations. Lowe's also announced that it was acquiring Foundation Building Materials, a distributor of interior building products, for about $8.8 billion. Estee Lauder slid 7.5% after the makeup and beauty company reported an 8% decline in sales in fiscal 2025 and a significant drop in adjusted per-share profit. The week's biggest news for Wall Street is likely arriving on Friday, when Federal Reserve Chair Jerome Powell will give a highly anticipated speech in Jackson Hole, Wyoming. The setting has been home to big policy announcements from the Fed in the past, and the hope on Wall Street is that Powell will hint that an interest rate cut is coming soon. The Fed has kept its main interest rate steady this year, primarily because of the fear of the possibility that President Donald Trump's tariffs could push inflation higher. But a surprisingly weak report on job growth across the country may be superseding that. In Europe, France's CAC 40 ticked up 0.2%, while Germany's DAX dipped 0.3%. Britain's FTSE 100 added more than 0.4% despite a report that said inflation in the U.K. rose more than expected through July, in part due to soaring airfares and food prices. Tokyo's benchmark Nikkei 225 declined 1.5% after Japan reported that its exports fell slightly more than expected in July, pressured by higher tariffs on goods shipped to the U.S. Imports also fell from a year ago. Tracking Tuesday's decline by Wall Street favorite Nvidia and other artificial-intelligence stars, Japanese computer-chip equipment makers Advantest plunged 5.7% and Disco Corp. dropped 4.9%. Chipmaker Tokyo Electron lost 1.4%. and Lasertec Corp. lost 1.7%. The Taiex in Taiwan fell 3.0% after chip maker TSMC dropped 4.2%. Hong Kong's Hang Seng gained nearly 0.2%, while the Shanghai Composite index gained 1.0% after China's central bank opted to keep its benchmark interest rate unchanged, as markets had expected. Chinese toy company Pop Mart International Group's shares traded in Hong Kong soared 12.5% after its CEO said its annual revenue could top $4 billion this year, more than quadrupling after more than doubling in the first half of the year. Its CEO also announced that the company was releasing a mini version of its popular Labubu dolls. South Korea's Kospi dropped 0.7% after North Korean leader Kim Jong Un condemned South Korean-U.S. military drills that began this week. He vowed a rapid expansion of his nuclear forces to counter rivals, according to North Korean state media.
Bloomberg
5 minutes ago
- Bloomberg
US Stocks Poised to Extend Losing Streak Ahead of Jackson Hole
Stocks headed for a fourth straight day of declines as investors questioned sky-high valuations amid a deluge of earnings reports from retailers, with a closely watched Federal Reserve symposium to come later this week. The S&P 500 Index was down 0.1% after the open, led by the information technology and consumer discretionary sectors. Target Corp. was the worst-performing stock in the index after the company picked an insider to lead a turnaround. The tech-heavy Nasdaq 100 Index fell 0.3%, extending losses after a sharp mega-cap led selloff a day earlier. The blue-chip Dow Jones Industrial Average rose 0.1%, trading near a record high.
